FAQ

liarozole

An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2017
051019922017

Related topics

Related topics

10 relations

Broader (5)

Androgen AntagonistsAntineoplastic Agents, HormonalDermatologic AgentsEnzyme Inhibitors
(More)
Liarozole Hydrochlorideliarozole fumarate

Narrower (3)

LiazalR 085246R 75251

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
liarozole
Imidazoles
Androgen Antagonists
Enzyme Inhibitors
Antineoplastic Agents, Hormonal
Dermatologic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Liarozole inhibits transforming growth factor-β3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures.
OBJECTIVE To investigate the impact of liarozole on transforming growth factor-β3 (TGF-β3) expression, TGF-β3 controlled… (More)
Is this relevant?
2012
2012
Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent.
OBJECTIVE To study the influence of liarozole on leiomyoma cell proliferation and extracellular matrix (ECM) gene expression in… (More)
Is this relevant?
2001
2001
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
BACKGROUND Palmoplantar pustular psoriasis (PPP) is a chronic, relapsing condition often recalcitrant to therapy. Synthetic… (More)
Is this relevant?
1999
1999
Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
1Alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] inhibits the proliferation of many cancer cells in culture, but not the aggressive… (More)
Is this relevant?
1998
1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
OBJECTIVES To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed… (More)
Is this relevant?
1997
1997
Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole.
Liarozole, a novel imidazole derivative, inhibits the cytochrome P450-dependent 4-hydroxylation of retinoic acid, resulting in… (More)
Is this relevant?
1996
1996
Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells.
Beta-carotene, canthaxanthin and retinoic acid (RA) inhibited growth of human DU145 prostate cancer cells by 45, 56 and 18… (More)
Is this relevant?
1994
1994
Modulation of all-trans retinoic acid pharmacokinetics by liarozole
Continuous oral dosing with all-trans retinoic acid (RA) is associated with a progressive decrease in plasma drug concentrations… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1994
1994
Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid.
The metabolism of 4-keto-all-trans-retinoic-acid (4-keto-RA), a biologically active oxygenated metabolite of all-trans-retinoic… (More)
Is this relevant?
1992
1992
Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid… (More)
Is this relevant?